Intravitreal bevacizumab for management of choroidal osteoma without choroidal neovascularization

Najafabadi, Farhad Fazel; Hendimarjan, Seyyed Moien; Zarrin, Yasaman; Najafabadi, Mohammadreza Fazel

doi:10.4103/2008-322x.176905

Cited by 11 publications

(3 citation statements)

References 17 publications

(23 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Given its rarity, there is a scarcity of publications regarding treatment options for choroidal osteoma without CNV; focal laser, transpupillary thermotherapy, bevacizumab, and ranibizumab intravitreal injections have all been investigated. [2][3][4][5][6] With regard to antivascular endothelial growth factor (VEGF) therapy, in a retrospective case series of 6 eyes with choroidal osteomaassociated SRF, Song et al [4] reported improved visual and anatomical outcomes following intravitreal injections of bevacizumab; to note, CNV was absent in all but one eye. Clinical response dictated a spectrum of 1, 2, or 3 injections spanning a mean follow up of approximately 11 months.…”

Section: Discussionmentioning

confidence: 99%

Non-neovascular subretinal fluid secondary to choroidal osteoma controlled with intravitreal aflibercept – A case report

Brody¹,

Avisar²,

Reich³

2019

cleverjournal

View full text Add to dashboard Cite

The aim of the study was to describe a case of subretinal fluid without neovascularization due to choroidal osteoma that was treated successfully with intravitreal aflibercept. Choroidal osteoma is an ossifying tumor that can cause visual impairment through several pathological mechanisms, including fluid accumulation under the retina, with or without choroidal neovascularization (CNV). We described a young adult man who presented with unilateral visual impairment due to choroidal osteoma without CNV, resistant to bevacizumab intravitreal injections, which showed a marked response to aflibercept. Our experience provides support for the use of aflibercept in the treatment of non-neovascular choroidal osteoma; this is the first report describing this encouraging result. Nevertheless, the current observation merits further research.

show abstract

Section: Discussionmentioning

confidence: 99%

Non-neovascular subretinal fluid secondary to choroidal osteoma controlled with intravitreal aflibercept – A case report

Brody¹,

Avisar²,

Reich³

2019

cleverjournal

View full text Add to dashboard Cite

show abstract

“…The role of anti-VEGF agents in this condition is unclear. However, successful treatment by the use of intravitreal anti-VEGF agents [56,57] or TTT [58] has been reported.…”

Section: Choroidal Osteomamentioning

confidence: 99%

Choroidal Neovascularization Associated with Rare Entities

Anvari

Naseripour

Falavarjani

2020

Choroidal Neovascularization

View full text Add to dashboard Cite

Choroidal nevi are usually found incidentally during routine ophthalmoscopic examination. The prevalence ranges from 4 to 8% in general white population [1,2] making it the most common benign melanocytic intraocular tumor in adults [3]. Clinically, choroidal nevi appear as flat or slightly elevated, round or oval pigmented gray-brown (and sometimes amelanotic) lesions with well-defined margins. They are located deep to the retina, evenly distributed in all four quadrants of fundus and more common in postequatorial region [4].Although mostly asymptomatic, choroidal nevi should be observed for possible malignant transformation [5]. They may result in decreased visual acuity by inducing secondary changes in overlying retinal pigment epithelium (RPE) and retina including RPE atrophy or secondary fibrous metaplasia, pigment epi-

show abstract

“…However, there are many drawbacks such as limited final visual acuity. Recently, several cases were treated with anti-vascular endothelial growth factor drugs used in age-related macular degeneration or diabetic macular edema such as bevacizumab or ranibizumab [34]. Najafabadi et al [3] reported improvement in a patient treated with intravitreal bevacizumab for choroidal osteoma without CNV.…”

mentioning

confidence: 99%